PSMA 1007 18F

18F‑PSMA is indicated for the detection of prostate cancer by PET/CT, offering high sensitivity and excellent image definition. Its predominantly hepatobiliary clearance reduces interference in the pelvic region, improving the assessment of local and locoregional lesions.

Production follows strict Good Manufacturing Practices (GMP), with controls that ensure sterility, radiochemical purity, and batch reproducibility. The result is a reliable radiopharmaceutical, suitable for clinical requirements and compatible with advanced diagnostic protocols.